+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

HIV Vaccines Market by Vaccine Type (Preventive, Therapeutic), Technology (Dna, Mrna, Peptide), Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5533222
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The HIV Vaccines Market is witnessing a period of transformation, with new research approaches, advanced technologies, and evolving policy frameworks converging to address one of the most persistent global health challenges. Senior decision-makers have an opportunity to shape this rapidly evolving landscape, where innovation aligns directly with public health imperatives.

Market Snapshot: HIV Vaccines Market Size and Growth

The HIV Vaccines Market grew from USD 940.05 million in 2024 to USD 1.06 billion in 2025. It is expected to continue expanding at a CAGR of 12.96%, reaching USD 1.95 billion by 2030. The market’s robust trajectory is driven by new advances in structural biology, immunogen engineering, and the adoption of adaptive clinical trial models. Investment is accelerating around late-stage clinical assets, encouraged by global harmonization efforts and growing regulatory flexibility. These emergent trends position the sector for meaningful expansion, impacting innovation pipelines and stakeholder partnerships worldwide.

Scope & Segmentation

  • Vaccine Types: Preventive vaccines (including inactivated virus, live attenuated virus, recombinant protein, virus-like particle), and therapeutic vaccines offering distinct clinical approaches.
  • Technologies: DNA vaccines for stability and ease of manufacturing, mRNA (conventional and self-amplifying) platforms enabling rapid antigen expression, peptide-based vaccines for precise targeting, and viral vector systems balancing potency with established delivery methods.
  • Routes of Administration: Intramuscular injections as the primary standard, as well as intranasal and subcutaneous routes under investigation for improved immune response at the site of viral entry.
  • End Users: Clinics (hospital-affiliated and standalone), private and public hospitals, research institutes, and pharmaceutical companies that facilitate both early development and commercialization.
  • Distribution Channels: Direct sales to strategic partners, online procurement platforms for streamlined purchasing, and retail pharmacies expanding public accessibility.
  • Regional Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Key Companies Profiled: Johnson & Johnson, Moderna, BioNTech SE, GlaxoSmithKline, Sanofi, Merck, Pfizer, Novavax, CureVac, Bavarian Nordic.

Key Takeaways for Senior Decision-Makers

  • Recent advances in immunogen design, structural analysis, and adjuvant chemistry are creating new pathways for vaccine development and longer-lasting immunity.
  • Cross-sector collaboration among public health agencies, biotechnology firms, funders, and regulatory bodies is reducing risk for late-stage development and facilitating rapid clinical trials.
  • Adoption of advanced digital health tools and real-world analytics is streamlining candidate selection, optimizing clinical study designs, and supporting broader trial participation.
  • Expansion of manufacturing capabilities—alongside policy incentives and emerging regional partnerships—enables diversified supply chains and greater market resilience.
  • Innovation in procurement and pooled purchasing agreements is promoting stability in vaccine pricing and accessibility, particularly for resource-limited regions.
  • Leading companies are leveraging expertise from other vaccine platforms, integrating advanced technologies with agile regulatory engagement to enhance product viability and market access.

Tariff Impact: United States 2025 Policy Effects

The introduction of new United States tariffs in 2025 is influencing both production and distribution for HIV vaccine manufacturers. With increased duties on raw materials and components, companies are reassessing their supply chains, investing in localized manufacturing, and pursuing nearshoring strategies to minimize disruptions. As import expenses rise, stakeholders are establishing partnerships with regional producers and implementing advanced procurement models to manage pricing volatility and maintain equitable distribution, especially in vulnerable markets.

Methodology & Data Sources

This analysis relies on a comprehensive, multi-layered research approach, including primary interviews with leading immunologists, vaccine industry experts, and policy authorities. Secondary data were aggregated from peer-reviewed journals, clinical trial registries, patent filings, and regulatory agency publications. Rigorous validation procedures, consistency reviews, and quality checks underpin the credibility and accuracy of each finding.

Why This Report Matters

  • Identify emerging opportunities and actionable trends in HIV vaccine innovation, technology selection, and commercialization strategies.
  • Support informed, strategic decision-making by providing granular segmentation by vaccine type, technology platform, administration route, end user, and region.
  • Benchmark your organization’s position against leading players, while anticipating regulatory, policy, and market access challenges.

Conclusion

The HIV Vaccines Market stands at a pivotal juncture, shaped by innovation, strategic alliances, and proactive policy adaptation. For decision-makers, engaging with these evolving dynamics is key to driving sustainable impact and advancing global health equity.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advancements in mRNA-based HIV vaccine candidates demonstrating broader immune responses and durable protection
5.2. Development of mosaic antigen formulations aiming to target multiple HIV strains with enhanced coverage
5.3. Integration of broadly neutralizing antibody inducement approaches into next generation HIV vaccine research pipelines
5.4. Adoption of nanoparticle delivery systems to improve antigen stability and targeted immune activation in HIV vaccines
5.5. Initiation of large scale clinical trials focusing on preventative HIV vaccines in high incidence regions of sub-Saharan Africa
5.6. Collaboration between biotechnology firms and academic institutions to accelerate HIV vaccine candidate development and testing
5.7. Emerging regulatory frameworks facilitating accelerated approval pathways for promising HIV vaccine candidates with strong safety profiles
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. HIV Vaccines Market, by Vaccine Type
8.1. Introduction
8.2. Preventive
8.2.1. Inactivated Virus
8.2.2. Live Attenuated Virus
8.2.3. Recombinant Protein
8.2.4. Virus-Like Particle
8.3. Therapeutic
9. HIV Vaccines Market, by Technology
9.1. Introduction
9.2. Dna
9.3. Mrna
9.3.1. Conventional Mrna
9.3.2. Self-Amplifying Mrna
9.4. Peptide
9.5. Viral Vector
10. HIV Vaccines Market, by Route Of Administration
10.1. Introduction
10.2. Intramuscular
10.3. Intranasal
10.4. Subcutaneous
11. HIV Vaccines Market, by End User
11.1. Introduction
11.2. Clinics
11.2.1. Hospital-Affiliated Clinics
11.2.2. Standalone Clinics
11.3. Hospitals
11.3.1. Private Hospitals
11.3.2. Public Hospitals
11.4. Pharmaceutical Companies
11.5. Research Institutes
12. HIV Vaccines Market, by Distribution Channel
12.1. Introduction
12.2. Direct Sales
12.3. Online Sales
12.4. Retail Pharmacies
13. Americas HIV Vaccines Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa HIV Vaccines Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific HIV Vaccines Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Johnson & Johnson, Inc.
16.3.2. Moderna, Inc.
16.3.3. BioNTech SE
16.3.4. GlaxoSmithKline plc
16.3.5. Sanofi S.A.
16.3.6. Merck & Co., Inc.
16.3.7. Pfizer Inc.
16.3.8. Novavax, Inc.
16.3.9. CureVac N.V.
16.3.10. Bavarian Nordic GmbH
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. HIV VACCINES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HIV VACCINES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HIV VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HIV VACCINES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. HIV VACCINES MARKET: RESEARCHAI
FIGURE 26. HIV VACCINES MARKET: RESEARCHSTATISTICS
FIGURE 27. HIV VACCINES MARKET: RESEARCHCONTACTS
FIGURE 28. HIV VACCINES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HIV VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HIV VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HIV VACCINES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HIV VACCINES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HIV VACCINES MARKET SIZE, BY INACTIVATED VIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HIV VACCINES MARKET SIZE, BY INACTIVATED VIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HIV VACCINES MARKET SIZE, BY LIVE ATTENUATED VIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HIV VACCINES MARKET SIZE, BY LIVE ATTENUATED VIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HIV VACCINES MARKET SIZE, BY RECOMBINANT PROTEIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HIV VACCINES MARKET SIZE, BY RECOMBINANT PROTEIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HIV VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HIV VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HIV VACCINES MARKET SIZE, BY DNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HIV VACCINES MARKET SIZE, BY DNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HIV VACCINES MARKET SIZE, BY CONVENTIONAL MRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HIV VACCINES MARKET SIZE, BY CONVENTIONAL MRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HIV VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HIV VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HIV VACCINES MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HIV VACCINES MARKET SIZE, BY PEPTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HIV VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HIV VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HIV VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HIV VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HIV VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HIV VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HIV VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HIV VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HIV VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITAL-AFFILIATED CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITAL-AFFILIATED CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HIV VACCINES MARKET SIZE, BY STANDALONE CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HIV VACCINES MARKET SIZE, BY STANDALONE CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HIV VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HIV VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL HIV VACCINES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL HIV VACCINES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL HIV VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL HIV VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL HIV VACCINES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL HIV VACCINES MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL HIV VACCINES MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL HIV VACCINES MARKET SIZE, BY ONLINE SALES, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL HIV VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL HIV VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS HIV VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS HIV VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES HIV VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES HIV VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 119. CANADA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 120. CANADA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 121. CANADA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
TABLE 122. CANADA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2030 (USD MILLION)
TABLE 123. CANADA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 124. CANADA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 125. CANADA HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 126. CANADA HIV VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 127. CANADA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 128. CANADA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 129. CANADA HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. CANADA HIV VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. CANADA HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 132. CANADA HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 133. CANADA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 134. CANADA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 135. CANADA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. CANADA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. MEXICO HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 138. MEXICO HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 139. MEXICO HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
TABLE 140. MEXICO HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2030 (USD MILLION)
TABLE 141. MEXICO HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 142. MEXICO HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 143. MEXICO HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 144. MEXICO HIV VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 145. MEXICO HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. MEXICO HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. MEXICO HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. MEXICO HIV VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. MEXICO HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 150. MEXICO HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 151. MEXICO HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 152. MEXICO HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 153. MEXICO HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. MEXICO HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL HIV VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL HIV VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA HIV VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA HIV VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. GERMANY HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 230. GERMANY HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 231. GERMANY HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
TABLE 232. GERMANY HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2030 (USD MILLION)
TABLE 233. GERMANY HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 234. GERMANY HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 235. GERMANY HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 236. GERMANY HIV VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 237. GERMANY HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 238. GERMANY HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 239. GERMANY HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. GERMANY HIV VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. GERMANY HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 242. GERMANY HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 243. GERMANY HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 244. GERMANY HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 245. GERMANY HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. GERMANY HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. FRANCE HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 248. FRANCE HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 249. FRANCE HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
TABLE 250. FRANCE HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2030 (USD MILLION)
TABLE 251. FRANCE HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 252. FRANCE HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 253. FRANCE HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 254. FRANCE HIV VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 255. FRANCE HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. FRANCE HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. FRANCE HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. FRANCE HIV VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. FRANCE HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 260. FRANCE HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 261. FRANCE HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 262. FRANCE HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 263. FRANCE HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. FRANCE HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA HIV VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA HIV VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 283. ITALY HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 284. ITALY HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 285. ITALY HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
TABLE 286. ITALY HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2030 (USD MILLION)
TABLE 287. ITALY HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 288. ITALY HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 289. ITALY HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 290. ITALY HIV VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 291. ITALY HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. ITALY HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. ITALY HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. ITALY HIV VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. ITALY HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 296. ITALY HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 297. ITALY HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 298. ITALY HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 299. ITALY HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 300. ITALY HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 301. SPAIN HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 302. SPAIN HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 303. SPAIN HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
TABLE 304. SPAIN HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2030 (USD MILLION)
TABLE 305. SPAIN HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 306. SPAIN HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 307. SPAIN HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 308. SPAIN HIV VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 309. SPAIN HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 310. SPAIN HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 311. SPAIN HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 312. SPAIN HIV VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 313. SPAIN HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 314. SPAIN HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 315. SPAIN HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 316. SPAIN HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 317. SPAIN HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 318. SPAIN HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 328. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 329. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 330. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 331. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 332. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 333. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 334. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 335. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 336. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 337. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 338. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 339. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
TABLE 340. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2030 (USD MILLION)
TABLE 341. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 342. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 343. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 344. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 345. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 346. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 347. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 348. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 349. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 350. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 351. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 352. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 353. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 354. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 355. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 356. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 357. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
TABLE 358. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2030 (USD MILLION)
TABLE 359. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 360. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 361. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 362. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 363. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 364. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 365. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 366. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 367. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 368. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY CLINICS, 2025-20

Samples

Loading
LOADING...

Companies Mentioned

  • Johnson & Johnson, Inc.
  • Moderna, Inc.
  • BioNTech SE
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Novavax, Inc.
  • CureVac N.V.
  • Bavarian Nordic GmbH

Table Information